Moderna Sinks Another 8% Even as Lead Investigator Calls Melanoma Vaccine Data “Transformational”
Moderna (MRNA) shares fell 8% despite Phase 3 data showing its melanoma vaccine, developed with Merck (MRK), reduced recurrence or death risk by 42%. The lead investigator called the results transformational, but the stock had already dropped 19% earlier in the week. Moderna trades at 39x forward sales, above its 5-year average of 7.7x. Analysts expect $3.3B in 2028 revenue. Further data is awaited from both companies.
How this was made
The 30-second read
Why it matters
The data, while positive, fell short of market hype, prompting an 8% pre‑market decline in Moderna shares and a broader reassessment of cancer vaccine valuations.
Market read
First report of pivotal Phase 3 oncology data; immediate price impact and sector‑wide implications for biotech investors.
What to watch
Potential partnership revenue, future data readouts, and Merck's broader immuno‑oncology portfolio.
Background
Moderna and Merck presented full Phase 3 data for the personalized melanoma vaccine intismeran at the European Society for Medical Oncology meeting.
Ticker impact
Moderna reported Phase 3 melanoma vaccine data showing a 42% reduction in recurrence or death, causing the stock to fall another 8% pre‑market.
likely continued downside as investors reassess the vaccine's commercial potential
Data is positive but below hype; the stock already dropped 19% on leak and fell another 8% on fresh results.
Merck co‑developed the melanoma vaccine with Moderna and presented the same Phase 3 results, making it a subject of the article.
potential slight downside pending market interpretation of the trial outcome
Merck's broader pipeline may offset the specific vaccine news, but the data could temper enthusiasm.
Market effects
Biotech sector may see heightened scrutiny of oncology vaccine pipelines.
U.S. biotech stocks could experience short‑term volatility.
Limited to investors tracking cancer immunotherapy developments.
Counterpoint
The 42% risk reduction could be a catalyst for long‑term upside if commercial rollout succeeds.
Key entities
- companyModerna
Developer of the personalized melanoma vaccine.
- companyMerck
Partner co‑developer of the vaccine.
- personDr. Georgina Long
Lead investigator who called the results transformational.
